Spero Therapeutics (SPRO) Change in Account Payables (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Change in Account Payables came in at -$476000.0 in Q1 2026, up 91.41% YoY from -$248681.5 in Q1 2025, and up 32.19% on a QoQ basis from -$702000.0 in Q4 2025.
Spero Therapeutics (SPRO) Change in Account Payables (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Change in Account Payables data on file, last reported at -$476000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 91.41% year-over-year to -$476000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (down 18.99% YoY) and the FY2025 annual result came in at -$6.6 million, down 211.56% from the prior year.
- Change in Account Payables advanced to -$476000.0 in Q1 2026, from -$702000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q1 2022 to a low of -$5.5 million in Q1 2025.
- A 5-year average of -$52000.0 and a median of -$34000.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2024 — Change in Account Payables soared 5064.71% — and 2025, when it slumped 428.26%.
- Tracing SPRO's Change in Account Payables over 5 years: stood at -$2.0 million in 2022, then soared by 113.98% to $275000.0 in 2023, then jumped by 342.18% to $1.2 million in 2024, then plunged by 157.73% to -$702000.0 in 2025, then soared by 32.19% to -$476000.0 in 2026.
- The last three Change in Account Payables figures came in at -$476000.0 (Q1 2026), -$702000.0 (Q4 2025), and $615000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | -62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62,000.00 |
| Jun 30, 2026 | -62,000.00 |
| Mar 31, 2026 | -476,000.00 |
| Mar 31, 2026 | -476,000.00 |
| Dec 31, 2025 | -702,000.00 |
| Dec 31, 2025 | -702,000.00 |
| Sep 30, 2025 | 615,000.00 |
| Sep 30, 2025 | 615,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Mar 31, 2025 | -5.54 Mn |
| Mar 31, 2025 | -5.54 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | -370,000.00 |
| Jun 30, 2024 | -370,000.00 |
| Mar 31, 2024 | 1.69 Mn |
| Mar 31, 2024 | 1.69 Mn |